PES Statement Supporting Access to Gender Care The Pediatric Endocrine Society supports a patient and family/caregiver-centered approach to healthcare for…
Read MoreMore Articles
Sarah Kelly DNP, APRN, NP-C Dr. Kelly is working her dream job! Living with type 1 diabetes since childhood, she always hoped to one day work with children with diabetes.…
Read More
FDA recall warning: April 6, 2023 Abbott pharmaceuticals has issued a warning impacting four million readers for glucose monitors after reports that devices were overheating and catching fire when patients…
Read More
March 2023: Pfizer announced a supply disruption of Pfizer’s Solu-Cortef® (hydrocortisone sodium succinate for injection, USP) 100 mg/2 mL (50 mg/mL) ACT-O[1]VIAL™ Single Dose Vial presentations and provide guidance on…
Read More
Dear Friends, As we spring forward towards the PES Annual Meeting, many of us in Canada and the United States moved the clocks ahead. In the United States, only Arizona…
Read More
Historical Tidbit: Philip Showalter Hench, MD (February 28, 1896-March 30, 1965) Submitted by Alan D. Rogol, MD, Ph.D Philip Hench administered cortisone to several patients with severe rheumatoid arthritis just…
Read More
Annie Gladding I am a first-year pediatric endocrinology fellow at Medical College of Wisconsin/Children’s Hospital of Wisconsin. I received my business degree from the University of Maryland College Park but…
Read More
Kim Clash, CPNP Kim Clash is a Board-Certified Pediatric Nurse Practitioner working in Pediatric Endocrinology, focusing on gender-affirming care. She holds a master’s degree from the Johns Hopkins School of…
Read More
Dexcom G7 In December 2022, the Dexcom G7 continuous glucose monitor system was cleared by the FDA for use in people age 2 and older with all diabetes mellitus…
Read More
Wegovy® (semaglutide) once weekly injection is a glucagon-like peptide 1 receptor agonist (GLP1-RA) approved by the FDA in June, 2021 for weight management in adults. Wegovy was approved in December,…
Read More
Difficulty filling prescriptions for diazoxide have been reported intermittently. Teva Pharmaceuticals reports that Proglycem® Oral Suspension 50 mg/mL 30 mL (NDC 00575-6200-30) is currently available. Providers may need to direct…
Read More